Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610577 · ClinicalTrials.gov registry record
Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 377,753
- Enrollment target
NCT07610577: Completed study, sponsored by Brigham and Women's Hospital.
NCT07610577 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 377,753 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07610577 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 377,753 participants
- Enrollment target
Study Summary
This study aims to describe temporal trends in the use and costs of clopidogrel, ticagrelor, and prasugrel in Germany and the United States.
Primary Outcome
To evaluate temporal trends in the age- and sex-standardized use of clopidogrel, ticagrelor, and prasugrel among adults initiating P2Y12 inhibitor therapy after acute myocardial infarction in Germany and the US between 2011 and 2024.
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel
- DRUG Ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377,753 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2026-05-31 |
What the finished NCT07610577 record still lists
NCT07610577 is an observational study that tracks outcomes without assigning an intervention. Its 377,753 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Clopidogrel is the first listed.
NCT07610577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07610577 about?
NCT07610577 is a clinical study titled "Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction". This study aims to describe temporal trends in the use and costs of clopidogrel, ticagrelor, and prasugrel in Germany and the United States.
What is the current status of trial NCT07610577?
This trial is currently completed. The enrollment target is 377,753 participants. The study started on 2025-11-01. Estimated completion is 2026-05-31.
What interventions are being tested in trial NCT07610577?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT07610577?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI